Prostate cancer screening. Why the controversy?
Publication
, Journal Article
Walther, PJ
Published in: Surg Oncol Clin N Am
April 1995
The development of new technologies has stimulated a crusade of screening for earlier detection of prostate cancer. This effort has resulted in controversy regarding its clinical use in this format. Until randomized clinical screening trials define the value of prostate cancer screening, clinicians who use screening approaches must gain a strong understanding of the natural history of the disease, the strengths and weaknesses of available screening methodologies, and epidemiologic considerations of prostate cancer risk.
Duke Scholars
Published In
Surg Oncol Clin N Am
ISSN
1055-3207
Publication Date
April 1995
Volume
4
Issue
2
Start / End Page
315 / 334
Location
United States
Related Subject Headings
- SEER Program
- Risk Factors
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Middle Aged
- Mass Screening
- Male
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Walther, P. J. (1995). Prostate cancer screening. Why the controversy? Surg Oncol Clin N Am, 4(2), 315–334.
Walther, P. J. “Prostate cancer screening. Why the controversy?” Surg Oncol Clin N Am 4, no. 2 (April 1995): 315–34.
Walther PJ. Prostate cancer screening. Why the controversy? Surg Oncol Clin N Am. 1995 Apr;4(2):315–34.
Walther, P. J. “Prostate cancer screening. Why the controversy?” Surg Oncol Clin N Am, vol. 4, no. 2, Apr. 1995, pp. 315–34.
Walther PJ. Prostate cancer screening. Why the controversy? Surg Oncol Clin N Am. 1995 Apr;4(2):315–334.
Published In
Surg Oncol Clin N Am
ISSN
1055-3207
Publication Date
April 1995
Volume
4
Issue
2
Start / End Page
315 / 334
Location
United States
Related Subject Headings
- SEER Program
- Risk Factors
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Middle Aged
- Mass Screening
- Male
- Humans